Inside Biotech Agenus
Scott Matusow | Apr 29, 2013 11:56AM ET
Today, we look into at a company that has an imminent catalyst, a number of important Phase II and Phase III data releases throughout 2013 and a product pipeline with potential to tap into a $17B market.
AgenusTHLD ) also has a similar therapy for patients with reoccurring Glioblastoma termed TH-302. TH-302 is a Tumor Hypoxia-Targeted Drug, which is also combined with AVASTIN (Bevacizumab) in a Phase I/II trial to treat brain cancer patients. Threshold is in the early stage with this study, but is anticipating positive data from TH-302 for this very devastating and malignant disease.
Glioblastoma is an indication in which safe and effective therapies are very much needed.
Other Catalysts This Year
Agenus has already reported positive Phase III results in late 2012 for the QS-21 Stimulon Adjuvant in GlaxoSmithKline's RTS,S for Malaria and has several other trials underway for additional indications. These catalysts include Phase III Mage A3 for Melanoma, and Phase III A3 for non-small cell lung cancer. Agenus is also partnered with GalaxoSmithKline for both of these indications. Furthermore, a Phase II HerpV trial for Genital Herpes is underway, with data due in the fourth quarter of 2013.
Speculating further into the future, Agenus has a Phase III trial for HZ/su for shingles with data due in 2014 and also 10 other undisclosed indications.
Financial Position
According to Agenus' latest financial report, the company recently retired its outstanding $39 million 8.00% senior secured convertible notes due August 2014. These Notes were exchanged for $10 million in cash, 2,500,000 shares of common stock and a twenty percent revenue interest from QS-21 Stimulon partnered programs. In addition, the company entered into two separate $5 million debt transactions for $10 million total in notes plus 500,000 share warrants. Following these transactions, Agenus' total debt obligation outstanding is $10 million, down from $39 million.
Agenus has a low float, which means that as traders gain interest in this stock, price appreciation should happen relatively quickly. Additionally, the small short interest shows that many traders realize the potential of this company and don't want to be caught short going into this data release. Also on a positive note, insiders hold a decent amount of the company, which is important in helping determine how much conviction the people running the company have in their own development.
Get The News You Want
Insider Transactions:
Garo Armen, the Chief Executive Officer of Agenus, acquired 250,277 shares on December 23, 2012 at a price of $4.33 per share. He has added additional shares as recently as March 31, 2013 and currently holds 927,400 shares total, worth over $4 million. The CEO purchasing a large amount is bullish and demonstrates that he is confident about the company going forward.
Charts And Indicators
Taking a look at the above 60-minute chart over the last 20 trading sessions, we can see that traders have been accumulating Agenus. The stock price has been climbing steadily heading into the May 1 data presentation. The accumulation/distribution line has broken out and is in an uptrend with volume increasing.
The above 100-day chart shows the stock is trading above its 50-, 100- and 200-day moving averages, and the Money Flow Index and Relative Strength Index are in a current uptrend. All of these indicators signal bullish sentiment going forward.
In my opinion, AGEN is on the verge of breaking out of a longer term wedge and believe that share price will increase quickly in the days leading into the catalyst. Of course, if data release is positive after May 1, we should also see a major increase in share price as investors speculate on AGEN's future.
Conclusion
In my opinion, AGEN offers investors and traders an interesting opportunity in 2013. With several catalysts spread throughout the year, traders will be able to capitalize on the increased speculated value of the company. From an investing standpoint, AGEN has a promising pipeline of products and have aligned themselves with powerful partners. I believe AGEN is one of the better small-cap biotechnology companies on the market and shows great potential going forward.
My short-term price target opinion is $5.50 per share heading into this Wednesday. On a good data release, I believe AGEN should reach $6.50 or so.
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.